Atyr Pharma Inc (ATYR) Stock Price & Analysis
Atyr Pharma Inc (ATYR) fell 1.23% to USD 0.5 as of September 8, 2026 at 12:04 UTC, according to Nexqual real-time market data.
ATYR last closed at USD 0.5; the session ranged USD 0.49–0.51 on volume of 253,799 shares. Market capitalization is —, with a 52-week range of USD 0.4–6.5 (NCM). Source: Nexqual, September 8, 2026 at 12:04 UTC.
Key Statistics (as of September 8, 2026 at 12:04 UTC)
| Price | USD 0.5 |
|---|---|
| Change | ▼ 1.23% (down) |
| Previous Close | USD 0.5 |
| Open | USD 0.5 |
| Day Range | USD 0.49 – 0.51 |
| 52-Week Range | USD 0.4 – 6.5 |
| Volume | 253,799 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (ATYR)
Nexqual's technical model rates ATYR "STRONG SELL" based on 0 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 12:04 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 46.27 (neutral) |
| vs SMA50 | Below (USD 0.53) |
| MACD | -0 (negative) |
From Atyr Pharma Inc's Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States.
- Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD.
- The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ATCH | AtlasClear Holdings, Inc. | USD 0.19 | ▲ 0.32% |
| LRMR | Larimar Therapeutics, Inc. | USD 3.83 | ▼ 1.03% |
| IXHL | Incannex Healthcare Inc. | USD 3.25 | ▼ 0.76% |
| CGTX | Cognition Therapeutics, Inc. | USD 1.03 | ▼ 1.9% |
| RZLT | Rezolute, Inc. | USD 4.58 | ▲ 0.44% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 12:04 UTC. This page is informational and not investment advice.